Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?

Background: Immune checkpoint inhibition (ICI) has significantly improved the survival of metastatic melanoma (MM) with a significant proportion of patients obtaining long-lasting responses. However, ICI also exposes patients to new, heavy, and sometimes irreversible toxicities. Thus, identifying th...

Descripción completa

Detalles Bibliográficos
Autores principales: De Risi, Ivana, Sciacovelli, Angela Monica, Guida, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599026/
https://www.ncbi.nlm.nih.gov/pubmed/36289687
http://dx.doi.org/10.3390/biomedicines10102424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599026/
https://www.ncbi.nlm.nih.gov/pubmed/36289687
http://dx.doi.org/10.3390/biomedicines10102424

Ejemplares similares